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b MAP5, Université Paris Descartes, Paris, FranceReceived 15 September 2017; received in revised form 25 October 2017; accepted 2 November 2017













0959-8049/ª 2017 The Author(s). Pu
creativecommons.org/licenses/by-nc-nd/Abstract Background: The Norwegian Breast Cancer Screening Program (NBCSP) was im-
plemented across the country in 2005 and has been criticised for potential ‘overdiagnosis’,
i.e. a breast cancer diagnosis that otherwise would not have been detected or treated in a wo-
man’s lifetime. We aimed to estimate overdiagnosis in the NBCSP based on the Norwegian
Women and Cancer (NOWAC) study using both questionnaire information and record link-
age information from NBCSP.
Method: For 124,978 women aged 49e79 years from the NOWAC study, information on
screened women could be cross-validated from the NBCSP database. Based on information
from the NOWAC questionnaire, unscreened women were further divided into those who
had mammograms taken only outside the NBCSP and those who had never had taken a
mammogram. Breast cancers diagnosed in 2005e2013 were identified through linkage to the
Cancer Registry of Norway; in situ or DCIS 417; invasive 2845; combined 3262. Cumulative
incidence rates (CIRs) for ages 49e79 years of breast cancer were compared using the log-rank
test.
Results: After exclusion of women with a family history of breast cancer, screened women had
a CIR of 9.7% for combined breast cancer, non-significantly lower compared with unscreened
women. Screened women had a 1.1% increased CIR or 13.0% increased relative risk of breast
cancer diagnosis (significant) compared with women who had never had a mammogram, but
for invasive breast cancer alone the difference was reduced to 0.2% (95% CI: 9.1; 8.8).
Invasive breast cancers were significantly smaller (<2.5 cm) in screened versus unscreened(E. Lund), aurelienakamura@gmail.com (A. Nakamura), jean-christophe.thalabard@mi.parisdescartes.fr
3
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E. Lund et al. / European Journal of Cancer 89 (2018) 102e112 103women. There was a borderline significant decrease in lymph node positive cancer among
screened (p Z 0.06).
Conclusion: The findings of no significant overdiagnosis combined with smaller tumours and
less lymph node metastases suggest that the prevailing view of overdiagnosis in the NBCSP
should be challenged.
ª 2017 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Background
Recently, concerns about the side-effects of national
breast cancer screening programs have increased [1],
including concerns about potential overdiagnosis.
Overdiagnosis is defined as a cancer diagnosis that is a
result of screening and that would not have been
detected in the woman’s lifetime if screening had not
taken place. The amount and severity of overdiagnosis is
heavily debated [2e4]. Several reviews and meta-ana-
lyses have been published over the last few years. An
independent meta-analysis of three early clinical trials
reported a 19% increased incidence of breast cancer
among screened women in the target screening popula-
tion (50e69 years), which decreased to 11% when
women older than the screening age limit were included
[2]. These figures were more dramatic in a 2013
Cochrane review, which reported an estimated over-
diagnosis and overtreatment of 30% [3]. However, the
2014 balance sheet from the EUROSCREEN working
group showed that women screened biennially from 50
to 69 years of age and then followed up for breast cancer
incidence until 79 years of age had only four over-
diagnosed cases out of 1000 screened women [4]. The
recent International Agency for Research on Cancer
monograph reported overdiagnosis estimates of
15e25% [5] similar to the estimates generated for the
Norwegian Breast Cancer Screening Program (NBCSP)
as part of an evaluation made by the Research Council
of Norway [6]. An ecological analysis from the SEER
registries in the United States reported even higher es-
timates [7]. In a recent systematic review published as
part of the development of the American Cancer Asso-
ciation guidelines [8], the conclusion was that there is
large uncertainty about the magnitude of overdiagnosis
associated with different screening strategies. The same
uncertainty of the estimates was expressed in a recent
review [9].
The potential for ecological fallacy attributable to the
extensive use of grouped data, e.g. geography as a proxy
for screening attendance, has often been neglected, and
resultant associations interpreted as causal. The rapid
increase and decrease of hormone replacement therapy
(HRT) use around year 2000 could also add to the un-
certainty of ecological analyses, as HRT reduces thesensitivity and specificity of mammography [10]. In
addition, most women with a family history of breast
cancer are under specific surveillance outside of national
screening programs; this is the case for a substantial
portion of women with a family history of breast cancer
in Norway [11]. As these women are followed regularly
outside the NBCSP, they should not be included in
analyses of overdiagnosis as unscreened. However, es-
timates of overdiagnosis should reflect the two different
subgroups among unscreened women, as in reality,
many unscreened women undergo opportunistic
screening or wild screening outside national screening
programs. Thus the best and most accurate reference
group should consist of women who have never had a
mammogram. Analyses of overdiagnosis should also
take into consideration that in situ diagnoses are
generally based on mammographic information, not
clinical examination, and that mammographic diagnoses
of in situ cancer are an expected effect of screening.
Indeed, such diagnoses allow for the detection and
removal of lesions before they progress to invasive
cancer. The progression rate to invasive breast cancer is
unknown, but early removal of in situ lesions should
reduce later incidence of invasive breast cancer [12].
The aim of this analysis was to determine the pres-
ence of overdiagnosis in the NBCSP during its first 9
years of national coverage (2005e2013) based on in-
formation from the Norwegian Women and Cancer
(NOWAC) study, one of the few studies with informa-
tion on mammograms performed within and outside a
national breast cancer screening program.
2. Methods
2.1. The Norwegian Breast Cancer Screening Program
The NBCSP started in 1996 in four Norwegian counties
as a pilot program and was fully implemented across the
country early in 2005. Women aged 50e69 years are
invited to be screened by digital mammography within
the NBCSP every other year. At the start of the study
period (2005), prevalence screening had just been
completed in the last two counties. Consequently, in the
study period all women were first invited or screened at
age 50 to 51.
E. Lund et al. / European Journal of Cancer 89 (2018) 102e1121042.2. Study populationdthe Norwegian Women and
Cancer study
The NOWAC study is a national population-based
cohort study which started in 1991 [13]. A random
sample of Norwegian women (n Z 172 748) filled in one
to three questionnaires during the period 1991 to 2013.
NOWAC participants who were aged 49 to 79 during
the first 9 years of national coverage of the NBCSP
(2005e2013) were selected for the present analysis. We
included women living in Norway with no previous
cancer diagnosis. In this analysis, the dates of NBCSP
mammograms were taken from the NBCSP database
through a linkage to NBCSP by the use of thee unique
national identifier or Norwegian personal number. In-
formation on non-NBCSP mammograms was taken
from the NOWAC questionnaires. The NOWAC ques-
tionnaires contained information on reproductive and
lifestyle factors, including maternal history of breast
cancer. Table 1 shows those that will be used for
adjustment as risk factors.
Death and emigration status were extracted from the
Cause of Death Registry and the Central Population
Registry at Statistics Norway. Cases of invasive and in
situ breast cancer were identified through linkage to the
Cancer Registry of Norway using the unique national
identifier or Norwegian personal number. The
124 978 women included in the analyses contributedTable 1
Characteristics of the study sample from the Norwegian Women and
Cancer cohort. The percentage number of women in each group
(screened within the Norwegian Breast Cancer Screening Program
(NBCSP), mammogram taken only outside the NBCSP, and never had
a mammogram) corresponds to the year 2005.
Characeristics Screened Outside Never
N 83,963 31,041 9974
Age N Z 83,938 N Z 31,041 N Z 9,974
48e52 10.5 68.0 73.5
53e59 56.0 18.8 10.8
60e69 30.1 7.4 5.4
70e84 3.4 5.8 10.4
Mother hist. of BC
Yes 5.4 6.8 2.5
No 94.6 92.2 97.6
Parity
0 8.1 10.3 10.0
1e2 52.8 55.7 49.8
2e3 35.7 31.5 35.6
5þ 3.4 2.4 4.6
Menopausal status
Postmenopausal 91.9 51.2 44.4
Premenopausal 8.1 48.8 55.6
Current use of HRT
Yes 18.6 14.4 7.3
No 81.4 85.6 92.7
BMI N Z 80,798 N Z 30,154 N Z 9,396
<25 52.1 57.4 5670
25þ 47.9 42.6 43.0
Abbreviations: BC, breast cancer; BMI, body mass index; HRT,
hormone replacement therapy.1 002 613 person-years at risk during the study period
(2005e2013). Study entry was defined as 1 January 2005
or the date of the first questionnaire answered after
that date. Study exit was defined as the date of cancer
diagnosis, emigration, death, or the end of 2013,
whichever occurred first.
The external validity was considered by comparing
the cumulative incidence rate curves for invasive breast
cancer in the NOWAC cohort with those published by
the Cancer Registry of Norway [14] for the period 2007
to 2013 in Fig. 1. The cumulative incidence rate were
non-significantly increased in the NOWAC study (log-
rank test, p Z 0.30).
2.3. Statistical analyses
Women were categorised as unscreened until their first
NBCSP mammogram, at which they were moved to the
screened category. This was taken into account in the
person-year calculation. However, once a woman was
classified as screened, she remained in the screened
group, even if she received a non-NBCSP mammogram
later. This was due to the lack of repeated question-
naires and national registers on mammograms taken
outside the NBCSP. Unscreened women consisted of two
sub-cohorts; women with non-NBCSP mammograms
only had an outside mammogram at time of recruit-
ment, and women who had never taken a mammogram
at time of recruitment. Analyses of the different groups
in relation to breast cancer incidence (in situ andFig. 1. Cumulative incidence rates for women participating in
NOWAC and national figures from the Cancer Registry of Nor-
way, 2009e2011. NOWAC, Norwegian Women and Cancer
study.
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lymph node status (yes/no) were performed based on
information from the Norwegian Cancer Registry.
Statistical analyses were run using SAS 9.4 (SAS
Institute, Cary NC, USA). We chose to divide age into
seven groups (49e52, 53e55, 56e59, 60e64, 65e69,
70e74, 75e79 years). The prevalence group was defined
as women who had their first NBSCP mammogram
between 49 and 52 years of age, since some women were
invited to the NBCSP for the first time at 52 years of
age. Cumulative breast cancer incidence rates were
calculated by summing the age-specific breast cancer
incidence rates [15]. The breast cancer incidence rate for
an age group was calculated as the number of new breast
cancer cases during the period 2005e2013 divided by the
number of women at risk during the same period. Rates
were reported per 100 000 person-years. Cumulative
breast cancer incidence rates across all age groups
combined were compared between the groups using log-
rank tests. Two groups were regarded as statistically
significantly different if a two-sided Chi-squared test p-
value was less than 0.05. Hazard ratios and 95% CIs
were obtained using Cox regression. Age was used as the
time-scale. Multivariate analyses were adjusted for
parity (0, 1e2, 3e4, 5 þ children), menopausal status
(premenopausal, postmenopausal), current HRT use
(yes, no) and body mass index (<25, 25þ) as given in the
questionnaire at the start of follow-up.Fig. 2. Age-specific breast cancer incidence rates per 100 000
person-years for screened and unscreened women: in situ and
invasive combined and invasive alone, the Norwegian Women and
Cancer cohort, 2005e2013.3. Results
Characteristics of the study population are given in
Table 1. The participants who never had a mammogram
group consisted of 9974 women out of a total of 124,978
women. They had less family history of breast cancer
and less use of current HRT than women with a
mammogram. During the study period, 3262 cases of
breast cancer were identified in the Cancer Registry of
Norway: 417 (12.8%) cases of in situ breast cancer and
2845 (87.2%) cases of invasive breast cancer. In situ
breast cancer made up 13.2% of all breast cancers among
screened women and 9.8% in unscreened women. Thus,
the breast cancer incidence rate for in situ breast cancer
was 42 per 100 000 person-years and 284 per 100 000
person-years for invasive breast cancer. For validation
purposes, we compared the NOWAC questionnaire in-
formation and the information on NBCSP mammo-
grams in the NBCSP database in a sample of 11 463
NOWAC participants aged 50 years or older. The results
showed that only 1.7% of the 8214 women who partici-
pated in the NBCSP denied their participation.3.1. Screened versus unscreened women
The age-specific incidence rates of invasive breast cancer
for screened and unscreened women are given in Fig. 2.Prevalence screening in Norway is directed at women
aged 49e52 years and corresponded with an increased
risk of breast cancer diagnosis for screened women
versus unscreened women (RR Z 1.49; 95% CI
1.18e1.88). In the other age groups, incidence rates in
unscreened women were slightly higher than those in
screened women. The incidence rates dropped among
screened women who were over the target screening age
and thus no longer invited to the NBCSP, i.e. 70 years of
age and over, but rates continued to grow for the
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RR Z 0.51; 95% CI 0.30e0.85). However, 5 years after
women left the NBCSP, an inverse trend was observed
in the incidence rates for screened and unscreened
women, converging to around 300 cases per 100 000
person-years (RR Z 0.93; 95% CI 0.61e1.44).
In an analysis combining in situ and invasive breast
cancer, unscreened women had a CIR of 10.8%
compared with 9.9% for screened women i.e. a differ-
ence of 0.92% (Table 2). A Cox regression analysis
comparing unscreened women to screened women
showed an 8% non-significant increased risk
(RR Z 1.08; 95% CI 0.96e1.22) without adjustmentTable 2
Number of breast cancer cases among study women by maternal history of
and cumulative incidence rates per 100 000 person-years, the Norwegian W
All women 49e52 53e55 56e5
Screened Cases 152 325 719
PY 38,693 130,880 234,9
Rate 393 248 306
Unscreened Cases 140 55 70
PY 53,024 17,519 19,78
Rate 264 314 354
Only women without mother history of breast cancer
Screened Cases 143 305 660
PY 36,987 124,623 222,8
Rate 387 245 296
In situ Cases 36 46 84
PY 36,987 124,623 222,8
Rate 97 37 38
Invasive Cases 107 259 576
PY 36,987 124,623 222,8
Rate 289 208 258
Unscreened Cases 123 46 63
PY 50,157 16,064 18,01
Rate 245 286 350
In situ Cases 10 4 4
PY 50,157 16,064 18,01
Rate 20 25 22
Invasive Cases 113 42 59
PY 50,157 16,064 18,01
Rate 225 261 328
Only outside Cases 102 39 55
PY 36,159 12,064 13,81
Rate 282 323 398
In situ Cases 10 4 4
PY 36,159 12,064 13,81
Rate 28 33 29
Invasive Cases 92 35 51
PY 36,159 12,064 13,81
Rate 254 290 369
Never taken a mammogram Cases 21 7 8
PY 13,997 4000 4198
Rate 150 175 191
In situ Cases 0 0 0
PY 13,997 4000 4198
Rate 0 0 0
Invasive Cases 21 7 8
PY 13,997 4000 4198
Rate 150 175 191and a 4% non-significant increased risk after adjustment
for cofactors (RR Z 1.04; 95% CI 0.92e1.18).
3.2. Family history of breast cancer
For the sub-cohort of women with a maternal history of
breast cancer, the cumulative incidence rates for all
cancers were 13.8% for screened versus 21.1% for un-
screened women (log-rank test, p < 0.001; data not
shown). After removing women with a maternal history
of breast cancer from the screened and unscreened
groups, the difference in cumulative incidence rates
became smaller (Table 2 and Fig. 3), 9.7% versusbreast cancer, screening status, age, person-years and incidence rates,
omen and Cancer cohort, 2005e2013.
9 60e64 65e69 70e74 75e79 Cumulative
rates %
952 578 77 49
22 271,073 142,982 37,511 16,012
351 404 205 306 9.9
61 30 18 36
6 16,942 7817 4462 10,992
360 384 403 328 10.8
870 533 72 46
31 256,185 135,134 35,621 15,209
340 394 202 302 9.7
109 63 3 4
31 256,185 135,134 35,621 15,209
43 47 8 26 1.3
761 470 69 42
31 256,185 135,134 35,621 15,209
297 348 194 276 8.4
50 28 15 34
5 15,480 7202 4266 10,541
323 389 352 323 10.2
6 2 2 6
5 15,480 7202 4266 10,541
39 28 47 57 1.1
44 26 13 28
5 15,480 7202 4266 10,541
284 361 305 266 9.1
42 22 9 24
8 12,033 5332 3085 6869
349 413 292 349 10.7
6 2 2 6
8 12,033 5332 3085 6869
50 38 65 87 1.5
36 20 7 18
8 12,033 5332 3085 6869
299 375 227 262 9.2
8 6 6 10
3447 1870 1181 3673
232 321 508 272 8.6
0 0 0 0
3447 1870 1181 3673
0 0 0 0 0.00
8 6 6 10
3447 1870 1181 3673
232 321 508 272 8.6
Fig. 3. Cumulative breast cancer incidence rates per 100 000
person-years according to screening status, in situ and invasive
combined and invasive alone, the Norwegian Women and Cancer
cohort, 2005e2013.
Fig. 4. Cumulative incidence rates of invasive breast cancer per
100 000 person-years for screened women and women who had
never had a mammogram, in situ and invasive combined and
invasive alone, the Norwegian Women and Cancer cohort,
2005e2013.
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breast cancer indicated a larger difference (p Z 0.13;
Fig. 3). The cumulative incidence rates for in situ breast
cancer were almost equal among screened and un-
screened women, 1.3% versus 1.10% (Table 2).
3.3. Women with mammograms taken only outside
NBCSP versus women who never had a mammogram
Subgroup analyses comparing women with non-NBCSP
mammograms to women who had never had a
mammogram showed a higher CIR (in situ and invasive
breast cancer combined) of 10.7% in the former group
and 8.6% in the latter group (Table 2). Most of this
difference was due to the lack of in situ among women
who never had a mammogram. The group of womenwho never had a mammogram had not one single
diagnosis of in situ.
3.4. Screened women versus those who never had a
mammogram
Combining in situ and invasive breast cancer in a com-
parison between screened and never-taken-a-mammo-
gram women yielded a difference in cumulative
incidence rate of 1.1% or a relative difference of 13.0%
(p < 0.01), Fig. 4. The cumulative incidence rate became
non-significant when restricted to invasive breast cancer
only; difference in CIR -0.2% (95% CI; 9.1% to 8.8%).
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When looking at the cumulative incidence of invasive
breast cancer stratified by tumour size and lymph node
status (Fig. 5), screened women had smaller tumours
(<2.5 cm) than unscreened women (p Z 0.01). There
was a borderline significant decrease in lymph node
involvement among screened women (p Z 0.06).
4. Discussion
In this analysis, women participating in the screening
program had a higher incidence for invasive and in situ
breast cancer combined compared with women who
never had a mammogram, a difference which disappeared
in the analysis restricted to invasive breast cancer only.Fig. 5. Cumulative incidence rates of breast cancer according to screeni
the Norwegian Women and Cancer cohort, 2005e2013.It is the only European cohort study that can discrimi-
nate between women screened, unscreened and never
taken a mammogram for proper comparisons of inci-
dence rates.
The validity of the analyses is partly dependent on the
prospective design of the NOWAC study. It is the only
national cohort study in Europe with a random sample
from the whole female population and with an accept-
able response rate [13]. This has given distributions of
major risk factors for breast cancer close to the expected
population values [16]. The cumulative incidence rate
curves for invasive breast cancer in the NOWAC cohort
were not statistically significantly different from those
published by the Cancer Registry of Norway. The slight
increase in cumulative breast cancer incidence could be
related to the increased proportion of women withng status (only invasive), tumour size and lymph node involvement,
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slightly higher incidence rate. The information on
mammograms in the screening program was based on a
linkage to the NBCSP database using a unique personal
identification number, the same as used for linkages to
cancer registry and for mortality, resulting in complete
coverages. For the first time, the non-screened, often
named control group, could be divided into two sub-
cohorts; women with a mammogram taken outside
screening, often named wild screening or in a clinical
situation, and those who never had a mammogram. The
high level of wild screening in Norway before and during
the years of introduction of NBCSP has been addressed
[17]. The lack of in situ diagnosis in the group who never
had taken a mammogram supports the validity of the
questionnaire information since the in situ diagnoses
depend on having taken a mammogram.
After the introduction of the NBCSP in four counties
in 1996, at least six studies [18e23] of overdiagnosis in
Norway have been published. As illustrated in Fig. 6,
the estimates of overdiagnosis have been reduced over
time with the last ones all under the estimate given by
the Norwegian Research Council of between 15% and
25% [6]. In Norway, the decrease in estimates may be
due to longer follow-up after the screening became na-
tional in 2005 and improved designs. A similar trend
was found for the mammographic screening in the
Netherlands with an estimate of 3.6% in 2006 [24]. In an
overview of mammographic screening in Europe, the
conclusion was that the most plausible estimates rangedFig. 6. Published estimates of overdiagnosis in the Norwegian Breas
analysis.from 1% to 10% covering the Netherlands, Italy, Spain,
Norway, Sweden, Denmark and UK [25]. It should be
noted that these results on overdiagnosis are quite
similar to those of a recently published randomised
controlled trial [26], which showed no differences in
breast cancer incidence for in situ or invasive breast
cancer. The UK Age trial recruited women aged 39e41
years in the 1990s with repeated screening up to 50
years, after which they were included in the ordinary
national breast cancer screening program. According to
the GRADE system [27], the change in methodology
from ecological analyses, to record linkage studies and
finally cohort analyses with both register information
and questionnaire information from those outside the
screening should improve the quality of evidence. The
impact of study design and the methods of calculation
have been used as an argument for the discrepancies on
overdiagnosis estimates as found in Denmark [28]. For
many countries, no specific estimates of overdiagnosis
are published with France as an example [29].
Analyses and estimates of overdiagnosis are clearly
dependent on the definitions of ‘participation or not’ in
the screening program. In most studies, the definition of
‘screened’ is based on ‘intention to screen’ analyses, in
which all women, or an estimated fraction in a certain
geographic area, are considered to be the part of the
screened group without any individual information.
This ‘intention to screen’ approach can inform us about
the public health implications of a screening program,
but it does not inform individual women about the riskt Cancer Screening Program [23e28] compared with the present
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present analysis took advantage of the unique oppor-
tunity to define the exact screening status of each
participant after the complete implementation of a na-
tional breast cancer screening program, including the
possibility to divide unscreened women into two sub-
cohorts. The overall comparisons showed a tendency for
more breast cancer in the unscreened group. However,
since the unscreened group included many women with
a maternal history of breast cancer, we considered it
important to exclude this high-risk group in our ana-
lyses. Indeed, in Norway, women with a maternal his-
tory of breast cancer are offered genetic guidance and
testing for genetic variants like BRC1, in addition to
annual clinical breast examinations, mammography and
eventually MRI. After we excluded women with a
maternal history of breast cancer, we observed reduced
cumulative incidence rates for both unscreened and
screened women, though the effect was stronger for
unscreened women. Another methodological issue was
the definition of screen-detected cancer. Women who
participated in the NOWAC study and were diagnosed
with a breast cancer after screening interval period of
more than 2 years were still counted as screened women.
We did not have the information on the reasons why
screened women stopped attending the NBCSP. It is
possible that they were screened either in a different
program, or were under specific surveillance, or decided
to stop for personal reasons. This might overestimate
the number of cases in the screened group. The cumu-
lative incidence rate of breast cancer diagnosed more
than 2 years after last mammogram was 0.4% for
women under 70 years of age (data not shown). These
cancers were diagnosed outside the screening program
as clinical cancer.
Lead time is defined as the time between early diag-
nosis with screening and when diagnosis would have
been made without screening. For Norway, lead time in
the national screening program has been estimated till
around five years [30]. Adjustment for lead-time bias can
be done in several ways. We choose to follow the pop-
ulation 10 years after the end of the screening program
till 79 years of age. We found a strong compensatory
drop.
When discussing the issue of overdiagnosis in
screening programs, it is important to mention the role
of in situ tumours, mainly ductal carcinoma in situ.
Screening presumes the existence of a silent disease
reservoir [31]. The detection of these tumours is one of
the primary goals of breast cancer screening, as they
cannot be detected clinically. Although the level of
progression from in situ to invasive breast cancer is
unknown [12], the diagnosis and removal of in situ tu-
mours should reduce progression to invasive cancer and
result in a lower incidence of invasive breast cancer in
older age groups. This was found in an ecological
analysis of local screening units of the national screeningprogram in England, Wales and Northern Ireland [32].
For every three screen-detected cases of ductal carci-
noma in situ, there was one fewer invasive interval
cancer in the next 3 years. Our results are compatible
with such a weak tendency.
Another important result was the finding that the
distribution of node-positive tumours and tumour size
were more favourable among screened women
compared with all unscreened women. These findings
indicate that the screening works as planned by reducing
the tumour burden of the screened population. The
borderline significant reduction in node involvement
could be important for the future mortality.
The NBCSP is a full-scale national program that uses
digital mammography as a screening test. It has been
shown that the number of unnecessary biopsies and
other investigations declined after the nationwide
introduction of digital mammography in Norway [33].
The percentage distribution of in situ and invasive breast
cancers that we observed was quite similar in the
screened and unscreened groups, supporting the view
that most unscreened women do have taken mammo-
grams, even if they are outside the NBCSP. One expla-
nation for the small differences in the percentage
distribution could be the strong time dependency of
HRT use in Norway. Around the year 2000, the use of
HRT increased rapidly, only to decline in subsequent
years. At that time, public prescription rules advocated a
mammogram before starting use of HRT. Also around
the year 2000, the population-attributable risk of breast
cancer related to current HRT use was estimated at 27%
based on the NOWAC study [34]. HRT can affect the
sensitivity of mammography, and changes in HRT use
have been linked to increased risks of recall, biopsy
rates, screen-detected cancers, and interval cancers [10].
The drop in HRT use could have improved the sensi-
tivity of the NBCSP during the study period.
A weakness of the present study is the limited sta-
tistical power for the analyses of unscreened women,
particularly for the very small group of women who
never had a mammogram. Another problem could be
the definition of women who never had a mammogram.
This was based on questionnaire information given at
the start of study period, and some of these women may
have been screened outside NBCSP or taken a clinical
mammogram thereafter. Women screened outside
NBCSP would give a misclassification and add women
with a mammogram to the group of women who never
had a mammogram. We have no information on the
number of women in this group. On the other hand, in
this analysis women who never had a mammogram had
no in situ breast cancer indicating that they have not had
any wild-screening investigations.
This analysis complements a previous analysis of
overdiagnosis in the NOWAC study based on ques-
tionnaire information only [21]. The present analysis
added register information from the NBCSP giving
E. Lund et al. / European Journal of Cancer 89 (2018) 102e112 111exact information on screening status, a larger study
population and longer follow-up.
Statistical estimations will hardly be able to solve the
problem of potential overdiagnosis, but they have
played an important role in pinpointing the need for
improved radiological and histopathological diagnostics
that can give differential diagnoses for growing and non-
growing tumours. The implication of the concept of
overdiagnosis is a postulate that current histopatho-
logical diagnostic is not sensitive enough for the differ-
ential diagnosis of overdiagnostic cases versus cases in
need of treatment. Consequently, the diagnosis of non-
growing or overdiagnosed tumours might be solved
through new independent tests [35,36] for breast cancer
that are based on tumour tissue or peripheral blood
using functional genomics.
5. Conclusion
Our analysis did not find evidence for overdiagnosis of
invasive breast cancer in the NBCSP. Screened women
had smaller tumours and less lymph node involvement.
The early detection of in situ tumours is a primary goal
of screening and should not be considered over-
diagnosis. The discussion of the negative health effects
of screening should focus on the potential problem of
overtreatment of in situ tumours.
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